Department of Hematology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang, Hebei, China.
Hebei Senlang Biotechnology Co, Shijiazhuang, China.
Front Immunol. 2024 Oct 14;15:1461908. doi: 10.3389/fimmu.2024.1461908. eCollection 2024.
Relapsed/refractory acute myeloid leukemia (R/R-AML) has a poor prognosis. CD7 is expressed in leukemic cells in 30% of patients with AML but not in normal myeloid cells. Therefore, it can be a potential target for immunotherapy in patients with R/R-AML. Naturally selected CD7-directed chimeric antigen receptor T cells (CAR-T) have promising effects against AML based on xenotransplantation models. We report a R/R-AML case that achieved complete remission with incomplete hematologic recovery with naturally selected CD7 CAR-T therapy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) as consolidation early after CAR T therapy, the patient experienced 12 months of disease-free survival to date. Our results confirmed that allogeneic hematopoietic stem cell transplantation after naturally selected CD7 CAR-T therapy can be a potential treatment for patients with CD7-positive R/R-AML.
复发/难治性急性髓系白血病（R/R-AML）预后不良。CD7 在 30%的 AML 患者的白血病细胞中表达，但不在正常髓系细胞中表达。因此，它可能成为 R/R-AML 患者免疫治疗的潜在靶点。基于异种移植模型，自然选择的 CD7 导向嵌合抗原受体 T 细胞（CAR-T）对 AML 具有有前景的疗效。我们报告了一例 R/R-AML 病例，该病例在接受自然选择的 CD7 CAR-T 治疗后实现了不完全血液学恢复的完全缓解。在 CAR-T 治疗后早期进行异基因造血干细胞移植（allo-HSCT）作为巩固治疗，患者至今已无疾病生存 12 个月。我们的结果证实，自然选择的 CD7 CAR-T 治疗后进行异基因造血干细胞移植可能是治疗 CD7 阳性 R/R-AML 患者的一种潜在方法。
